Evidence map›Paper›PMID 37627108›Full record

ReviewCancers2023

Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications.

Sifon Ndon, Amritpal Singh, Patrick K Ha, Joyce Aswani, Jason Ying-Kuen Chan, Mary Jue Xu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Advancements in immunotherapy for oropharyngeal cancer: Current landscape and future prospects.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. International Trends in Head and Neck Cancer Mortality.JAMA otolaryngology-- head & neck surgery · 2026
    Observational
  8. Article
  9. Patient-reported outcomes in oropharyngeal cancer: comparing two cohorts with different treatment protocols.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Sifon NdonDepartment of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA 94115, USA.
Amritpal SinghSchool of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Patrick K HaDepartment of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA 94115, USA.
Joyce AswaniDepartment of Surgery, University of Nairobi, Nairobi 00100, Kenya.
Jason Ying-Kuen ChanDepartment of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-9480-4637
Mary Jue XuDepartment of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA 94115, USA.
University of California, San Francisco · USChinese University of Hong Kong · HKUniversity of Nairobi · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms. Epidemiologic studies have noted regional variations in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). While HPV vaccination remains the main preventative approach, vaccination policy in relation to gender neutrality is heterogeneous and particularly sparse in low- and middle-income countries, where the burden of global cancer cases and HPV-associated HNC are not well-characterized in certain regions. This review summarizes the existing literature on regional variations of HPV-associated OPSCC and gender-neutral vaccine policies. Based on available data, the incidence of HPV-associated OPSCC is highest in North America, Europe, and Oceania. As of 2022, 122 of 195 (63%) World Health Organization (WHO) member states had incorporated HPV vaccinations nationally; of these, 41 of 122 (34%) member states have introduced gender-neutral vaccine coverage. Future research is needed to describe continued evolving trends in HPV-associated OPSCC, understand underlying risk factors leading to regional variation in disease, and implement gender-neutral policy more broadly.

Indexed as

gender-neutral vaccination policyhuman papillomavirusoropharyngeal cancer

Identifiers

PMID37627108
PMCPMC10452639
OpenAlexW4385805594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.